AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20630162 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment for 4-5 year olds
Number of subjects: 135
Study 20630162 — intervention group
Group type: EXPERIMENTAL
Intervention: Added sugar intake assessment
Number of subjects: 135
Study 20630162 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweetened beverage intake comparison between overweight and normal weight children
Number of subjects: 135
Study 20630162 — intervention group
Group type: EXPERIMENTAL
Intervention: Television viewing time assessment
Number of subjects: 135
Study 20630162 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or vigorous activity assessment
Number of subjects: 135
Study 17392729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice (200 ml t.i.d. for 10 days)
Number of subjects: 10
Study 17392729 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 10
Study 17392729 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry juice
Number of subjects: 10
Study 16334158 — intervention group
Group type: EXPERIMENTAL
Intervention: 111In-HMFG1-F(ab')2 with lysine co-infusion
Number of subjects: 23
Study 16334158 — intervention group
Group type: COMPARATOR
Intervention: 111In-HMFG1-F(ab')2 without lysine co-infusion
Number of subjects: 23
Study 12468959 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg/4 h intravenously for 7 days)
Number of subjects: 16
Study 12468959 — intervention group
Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt
Number of subjects: 16
Study 9579004 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief educational intervention to increase fruit and vegetable consumption
Number of subjects: 276
Study 9579004 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual service without intervention)
Number of subjects: 276
Study 7806203 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (DPH)
Number of subjects: 68
Study 7806203 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 68
Study 7806203 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 68
Study 7806203 — intervention group
Group type: COMPARATOR
Intervention: Healthy age-matched male controls
Number of subjects: 68
Study 2496484 — intervention group
Group type: EXPERIMENTAL
Intervention: Moss nasoduodenal tube placement with esophagogastric decompression and immediate enteral feedings (Group 1)
Number of subjects: 50
Study 2496484 — intervention group
Group type: COMPARATOR
Intervention: No nasoduodenal tube placement (Group 2)
Number of subjects: 50
Study 2496484 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 1202192 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase heart-rate group
Number of subjects: 32
Study 1202192 — intervention group
Group type: EXPERIMENTAL
Intervention: Decrease heart-rate group
Number of subjects: 32
Study 1202192 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial session
Number of subjects: 32
Study 30859221 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 0
Study 30859221 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 27884802 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Policy
Number of subjects: 4363
Study 27884802 — intervention group
Group type: COMPARATOR
Intervention: Standard Policy
Number of subjects: 4363
Study 25530502 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal-bereavement-support DVD
Number of subjects: 18
Study 25530502 — intervention group
Group type: COMPARATOR
Intervention: Standard bereavement care (controls)
Number of subjects: 18
Study 25530502 — intervention group
Group type: EXPERIMENTAL
Intervention: DVD nonviewers
Number of subjects: 18
Study 24171982 — intervention group
Group type: EXPERIMENTAL
Intervention: One-visit endodontic treatment
Number of subjects: 100
Study 24171982 — intervention group
Group type: COMPARATOR
Intervention: Two-visit endodontic treatment
Number of subjects: 100
Study 22379833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dahuangzhechong pills
Number of subjects: 62
Study 22379833 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy
Number of subjects: 62
Study 19646862 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta without antithrombotic therapy
Number of subjects: 0
Study 19646862 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta with antithrombotic therapy
Number of subjects: 0
Study 19646862 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving epoetin)
Number of subjects: 0
Study 16456674 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO solution
Number of subjects: 32
Study 16456674 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g EAA mixture
Number of subjects: 32
Study 16456674 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO + EAA supplement
Number of subjects: 32
Study 16456674 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 32
Study 14743972 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose theophylline (USRT)
Number of subjects: 8
Study 14743972 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses theophylline (USRT)
Number of subjects: 8
Study 11185672 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination metformin/glyburide tablets (500 mg/2.5 mg and 500 mg/5 mg)
Number of subjects: 0
Study 11185672 — intervention group
Group type: COMPARATOR
Intervention: Metformin/glyburide (500 mg/5 mg) tablet with food
Number of subjects: 0
Study 11185672 — intervention group
Group type: COMPARATOR
Intervention: Metformin/glyburide (500 mg/5 mg) tablet in fasted condition
Number of subjects: 0
Study 9382122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 0.5 mg
Number of subjects: 125
Study 9382122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 1 mg
Number of subjects: 125
Study 9382122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate 2 mg
Number of subjects: 125
Study 9382122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (all doses)
Number of subjects: 125
Study 9382122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (2 mg)
Number of subjects: 125
Study 9382122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 1550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal continuous 17 beta‐estradiol, 0.05 mg/day, with transdermal cyclic norethindrone acetate, 0.25 mg/day
Number of subjects: 61
Study 1550171 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral continuous conjugated equine estrogens, 0.625 mg/day, with oral cyclic dl‐norgestrel, 0.15 mg/day
Number of subjects: 61
Study 1550171 — intervention group
Group type: COMPARATOR
Intervention: Control group (29 untreated subjects)
Number of subjects: 61
Study 3560612 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nifedipine (corinfar)
Number of subjects: 0
Study 3560612 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol (anaprilin)
Number of subjects: 0
Study 3560612 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg propranolol and 20 mg nifedipine
Number of subjects: 0
Study 3560612 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg propranolol (anaprilin) and 30 mg nifedipine (corinfar)
Number of subjects: 0
Study 3560612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31056685 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Bifidobacterium lactis, 109 colony‐forming units per capsule) for 8 weeks
Number of subjects: 73
Study 31056685 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics
Number of subjects: 73
Study 31056685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 28443834 — intervention group
Group type: COMPARATOR
Intervention: None (G2)
Number of subjects: 36
Study 28443834 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine (30s) (G3)
Number of subjects: 36
Study 28443834 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged primer application (1 min) (G4)
Number of subjects: 36
Study 28443834 — intervention group
Group type: EXPERIMENTAL
Intervention: Roughening with a diamond bur (G5)
Number of subjects: 36
Study 28443834 — intervention group
Group type: EXPERIMENTAL
Intervention: 10.5% NaOCl (1 min) (G6)
Number of subjects: 36
Study 25716646 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to McDonald's Happy Meal® adverts depicting healthy meal bundles (fish fingers, fruit bag, mineral water)
Number of subjects: 59
Study 25716646 — intervention group
Group type: COMPARATOR
Intervention: Control condition (exposure to ten toy adverts)
Number of subjects: 59
Study 25716646 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to food adverts
Number of subjects: 59
Study 24370154 — intervention group
Group type: EXPERIMENTAL
Intervention: 240‐mg/mL contrast material at 80 kVp
Number of subjects: 109
Study 24370154 — intervention group
Group type: EXPERIMENTAL
Intervention: 300‐mg/mL contrast material at 80 kVp
Number of subjects: 109
Study 24370154 — intervention group
Group type: EXPERIMENTAL
Intervention: 370‐mg/mL contrast material at 120 kVp
Number of subjects: 109
Study 22943970 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-1229 10 mg after a high-fat meal
Number of subjects: 72
Study 22943970 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-1229 (various doses: 1.25, 2.5, 5, 10, 20, 40, 60 mg)
Number of subjects: 72
Study 22943970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 22943970 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-1229 (various doses)
Number of subjects: 72
Study 19740126 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg/day
Number of subjects: 584
Study 19740126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study 17332965 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic scalpel
Number of subjects: 50
Study 17332965 — intervention group
Group type: EXPERIMENTAL
Intervention: High light intensity
Number of subjects: 50
Study 17332965 — intervention group
Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 50
Study 17332965 — intervention group
Group type: COMPARATOR
Intervention: Low light intensity
Number of subjects: 50
Study 15333074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing from the pulmonary vein (PV) at cycle lengths of 700 ms
Number of subjects: 20
Study 15333074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing from the pulmonary vein (PV) at cycle lengths of 300 ms
Number of subjects: 20
Study 15333074 — intervention group
Group type: COMPARATOR
Intervention: Control group pacing from the distal coronary sinus at 700 ms
Number of subjects: 20
Study 15333074 — intervention group
Group type: COMPARATOR
Intervention: Control group pacing from the distal coronary sinus at 300 ms
Number of subjects: 20
Study 11605809 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten 200 mg twice daily
Number of subjects: 45
Study 11605809 — intervention group
Group type: COMPARATOR
Intervention: Cefixime 200 mg twice daily
Number of subjects: 45
Study 9467759 — intervention group
Group type: EXPERIMENTAL
Intervention: High homophobia individuals
Number of subjects: 3
Study 9467759 — intervention group
Group type: COMPARATOR
Intervention: Medium homophobia individuals
Number of subjects: 3
Study 9467759 — intervention group
Group type: COMPARATOR
Intervention: Low homophobia individuals
Number of subjects: 3
Study 18800460 — intervention group
Group type: EXPERIMENTAL
Intervention: losartan 50 mg
Number of subjects: 135
Study 18800460 — intervention group
Group type: COMPARATOR
Intervention: lisinopril 20 mg
Number of subjects: 135
Study 18800460 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide 25 mg
Number of subjects: 135
Study 2653175 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg naloxone hydrochloride
Number of subjects: 54
Study 2653175 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg naloxone hydrochloride
Number of subjects: 54
Study 2653175 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg naloxone hydrochloride (single blind)
Number of subjects: 54
Study 794422 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Mycoplasma pneumoniae vaccine, 1-ml dose administered by jet-injection device.
Number of subjects: 7861
Study 794422 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (placebo) administered similarly to control subjects.
Number of subjects: 7861
Study 794422 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated Mycoplasma pneumoniae vaccine
Number of subjects: 7861
Study 28940403 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy (PEG)
Number of subjects: 214
Study 28940403 — intervention group
Group type: COMPARATOR
Intervention: Radiologically Inserted Gastrostomy (RIG)
Number of subjects: 214
Study 28940403 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 214
Study 26252534 — intervention group
Group type: EXPERIMENTAL
Intervention: ASM-024 50 mg
Number of subjects: 24
Study 26252534 — intervention group
Group type: EXPERIMENTAL
Intervention: ASM-024 200 mg
Number of subjects: 24
Study 26252534 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23589742 — intervention group
Group type: EXPERIMENTAL
Intervention: Home death preference
Number of subjects: 310
Study 23589742 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with at least one relative
Number of subjects: 310
Study 23589742 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom burden two days before death
Number of subjects: 310
Study 23589742 — intervention group
Group type: COMPARATOR
Intervention: Quality of care on standard hospital wards
Number of subjects: 310
Study 21727232 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (12-week treatment)
Number of subjects: 160
Study 21727232 — intervention group
Group type: COMPARATOR
Intervention: Placebo (12-week treatment)
Number of subjects: 160
Study 19853689 — intervention group
Group type: EXPERIMENTAL
Intervention: M118
Number of subjects: 0
Study 19853689 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 16732081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fructose infusion (0.5 g . kg(‐1) . h(‐1) for 4 h, starting 3 h before induction of anesthesia)
Number of subjects: 40
Study 16732081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fructose infusion
Number of subjects: 40
Study 16732081 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 40
Study 14715339 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 10003
Study 14715339 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 10003
Study 11374137 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Assisted Thoracoscopy (VATS)
Number of subjects: 40
Study 11374137 — intervention group
Group type: COMPARATOR
Intervention: Insertion of Chest Tube (ICT)
Number of subjects: 40
Study 9228213 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100 mg per day
Number of subjects: 45
Study 9228213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8015690 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparan sulfate
Number of subjects: 80
Study 8015690 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 80
Study 6418110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 15
Study 6418110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 6418110 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (after placebo)
Number of subjects: 15
Study 31854292 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the RESPECT intervention (three sessions of 1 hour)
Number of subjects: 72
Study 31854292 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (control arm)
Number of subjects: 72
Study 31854292 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus the RESPECT intervention
Number of subjects: 72
Study 29122190 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback screens with flight path of all target aircraft and triangular graphs of both RCJ scores and human performance (Group A)
Number of subjects: 0
Study 29122190 — intervention group
Group type: COMPARATOR
Intervention: Feedback screens with flight path of all target aircraft only (Group B)
Number of subjects: 0
Study 27697878 — intervention group
Group type: EXPERIMENTAL
Intervention: YP Face IT online psychosocial intervention
Number of subjects: 0
Study 27697878 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 0
Study 24747297 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ppb NO2
Number of subjects: 19
Study 24747297 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 ppb NO2
Number of subjects: 19
Study 24747297 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 19
Study 22089105 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) monotherapy for 9 weeks
Number of subjects: 569
Study 22089105 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol monotherapy for 9 weeks
Number of subjects: 569
Study 22089105 — intervention group
Group type: COMPARATOR
Intervention: Add-on therapy with HCTZ after atenolol
Number of subjects: 569
Study 22089105 — intervention group
Group type: COMPARATOR
Intervention: Add-on therapy with atenolol after HCTZ
Number of subjects: 569
Study 19770623 — intervention group
Group type: COMPARATOR
Intervention: Foreskin surface area in the lowest quartile (≤26.3 cm²)
Number of subjects: 965
Study 19770623 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreskin surface area in the second quartile (26.4-35.0 cm²)
Number of subjects: 965
Study 19770623 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreskin surface area in the third quartile (35.2-45.5 cm²)
Number of subjects: 965
Study 19770623 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreskin surface area in the highest quartile (>45.6 cm²)
Number of subjects: 965
Study 19770623 — intervention group
Group type: COMPARATOR
Intervention: Comparison of highest quartile (>45.6 cm²) to lowest quartile (≤26.3 cm²)
Number of subjects: 965
Study 17233848 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 195
Study 17233848 — intervention group
Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 195
Study 16199188 — intervention group
Group type: EXPERIMENTAL
Intervention: TKA731 (150 mg daily)
Number of subjects: 87
Study 16199188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 15206646 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.50% twice daily
Number of subjects: 31
Study 15206646 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 31
Study 15206646 — intervention group
Group type: COMPARATOR
Intervention: Comparison of latanoprost to betaxolol
Number of subjects: 31
Study 11775949 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 300 mg plus misoprostol 1,200 micrograms over 6 days
Number of subjects: 1621
Study 11775949 — intervention group
Group type: COMPARATOR
Intervention: Mifepristone 150 mg plus misoprostol 600 micrograms over 3 days
Number of subjects: 1621
Study 8721493 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine injections (0.1 micrograms each)
Number of subjects: 40
Study 8721493 — intervention group
Group type: COMPARATOR
Intervention: Saline injections (control)
Number of subjects: 40
Study 1807007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (100 mg x 3 per day)
Number of subjects: 6
Study 1807007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (25 mg x 3 per day)
Number of subjects: 6
Study 1807007 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine (20 mg x 2 per day in slow releasing form)
Number of subjects: 6
Study 6338381 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-drug regimen (modified LSA2-L2)
Number of subjects: 234
Study 6338381 — intervention group
Group type: COMPARATOR
Intervention: 4-drug regimen (COMP)
Number of subjects: 234
Study 31647384 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 190
Study 31647384 — intervention group
Group type: COMPARATOR
Intervention: Attention control group (physical activity recommendations)
Number of subjects: 190
Study 30289287 — intervention group
Group type: EXPERIMENTAL
Intervention: NI-071 (infliximab biosimilar)
Number of subjects: 0
Study 30289287 — intervention group
Group type: COMPARATOR
Intervention: Infliximab reference product (RP)
Number of subjects: 0
Study 26818533 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness and compassion meditation (LKM/CM)
Number of subjects: 0
Study 26818533 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness continuation training (control group)
Number of subjects: 0
Study 25795948 — intervention group
Group type: EXPERIMENTAL
Intervention: Cowpea protein isolate (25 g/day)
Number of subjects: 38
Study 25795948 — intervention group
Group type: COMPARATOR
Intervention: Casein (25 g/day)
Number of subjects: 38
Study 23348922 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel anticoagulants (specific types not mentioned) in PROBE trials
Number of subjects: 0
Study 23348922 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel anticoagulants (specific types not mentioned) in double-blind trials
Number of subjects: 0
Study 23348922 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (VKA) control in PROBE trials
Number of subjects: 0
Study 23348922 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (VKA) control in double-blind trials
Number of subjects: 0
Study 20697787 — intervention group
Group type: EXPERIMENTAL
Intervention: Language concordant group
Number of subjects: 191
Study 20697787 — intervention group
Group type: COMPARATOR
Intervention: Language discordant group
Number of subjects: 191
Study 19711135 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived susceptibility to chronic kidney disease (CKD) assessed via questionnaire
Number of subjects: 195
Study 19711135 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure management adherence assessed via Hill-Bone blood pressure adherence scale
Number of subjects: 195